Jonathan Alspaugh, Aeglea BioTherapeutics president and CFO
June 22, 2023 10:59 AM EDT
Financing
Startups
Deals

Ae­glea Bio­Ther­a­peu­tics ac­quires start­up Spyre in bid to go af­ter Mer­ck’s Prometheus, Roivant’s Tela­vant

Kyle LaHucik

Senior Reporter

Af­ter putting up the strate­gic al­ter­na­tive signs in April, rare dis­ease drug de­vel­op­er Ae­glea Bio­Ther­a­peu­tics is now look­ing to go in a new di­rec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times